For citations:
Avxentyev N.A., Makarova Yu.V. Cost-effectiveness analysis of encorafenib and binimetinib combination as first-line treatment for metastatic or unresectable BRAF V600-mutated metastatic melanoma in Russia. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):375-385. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.202
Views PDF (Rus): 334
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 